Galapagos intends to shutter its cell therapy business, which would affect about 365 employees across Europe, the United States and China and include site closures in New Jersey and Pennsylvania.
All entries for: Galapagos
January 8, 2025
Galapagos - Cambridge
Discontinued Research, Layoffs
Cambridge, MA
1,001-5,000 employees
“To advance its goal of becoming a global leader in cell therapy in oncology, Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over its small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.”
2 Discontinued Research Programs
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Small Molecule
January 8, 2025
Galapagos - Mechelen
Layoffs
Mechelen, Belgium
501-1,000 employees
Galapagos intends to reorganize its business to focus on long-term value creation in cell therapy in oncology. This is anticipated to lead to a reduction of approximately 300 positions.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule